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See Article, pages 160–166For decades there was no effective drug treatment for patients
with cholestatic liver disease apart from ursodeoxycholic acid
in primary biliary cirrhosis [1]. However, with new insights into
the molecular mechanisms of bile formation including the eluci-
dation of the nature, localization, function, and transcriptional
regulation of the major transport proteins and better understand-
ing of the pathophysiology of speciﬁc cholestatic liver diseases, a
new era of drug therapy in cholestasis and associated complica-
tions has dawned [2,3]. The attendant optimism is, at least in
part, based on the development of novel ‘‘designer’’ drugs that
are speciﬁc ligands to deﬁned nuclear receptors regulating hepa-
tobiliary metabolism and excretion of biliary compounds, in par-
ticular of bile acids. These drugs will signiﬁcantly increase the
pharmacological options available in this particular situation
and are also likely to have far-reaching medical implications in
other, much more prevalent conditions such as the metabolic
syndrome or non-alcoholic steatohepatitis [4]. Eventually, thera-
peutic nihilism in cholestatic liver diseases, especially in cholan-
giopathies, should become a thing of the past.
As the term cholestasis, meaning stasis of bile ﬂow, already
indicates, we still consider secretory failure of the liver at the level
of hepatocytes or cholangiocytes as the pathophysiological hall-
mark of cholestatic liver diseases. It may lead to cell injury, inﬂam-
mation, the biliary type of liver ﬁbrosis with portal hypertension,
and ﬁnally may cause end-stage liver disease and liver failure. A
variety of factors, some unidentiﬁed, may account for these com-
plicatedprocesses. Among themare retainedpotentially toxic cho-
lephils such as bile acids, ROS production, cytokines/chemokines
and their receptors, which may attract inﬂammatory cells, bile
duct proliferation, activated myoﬁbroblasts, increased biliary
pressure, or dysbiosis. This complexity obviously is a major obsta-
cle in ﬁnding useful treatment strategies. In fact it seems unrealis-
tic to aim to design a ‘‘one pill’’ approach for the heterogeneous
group of cholestatic liver diseases. Conceivable targets for drugJournal of Hepatology 20
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Open access under CC BY-NC-ND license.therapy for these challenging patients include: (i) restoration of
regular bile ﬂow, (ii) reduction of the potential toxicity of bile with
choleretic and thereby bile diluting drugs or increased phospho-
lipid and glutathione (GSH) secretion; (iii) stimulation of alterna-
tive export of potentially toxic biliary compounds via basolateral
hepatocyte transport and facilitated renal excretion via stimulated
glucuronidation and sulfatation, which should be particularly
helpful in hepatocellular cholestasis; (iv) reduction of inﬂamma-
tion; and (v) attenuation of ductular reaction along with an over-
whelming wound healing process or dissolution of liver ﬁbrosis.
For part of those treatment goals theirmolecular targets have been
identiﬁed (Fig. 1). With these complexmechanisms inmind,Wee-
rachayphorn et al. used common bile duct-ligated (BDL) mice to
study the effects of oltipraz (4-methyl-5(pyrazinyl-2)-1-2-
dithiole-3-thione), a promising candidate for drug therapy in
cholestatic liver diseases with potentially beneﬁcial pleotropic
effects [5]. The molecular effects among others include the induc-
tion of phase II detoxifying enzymes, UDP-glucuronyltransferase
and glutathione-S-transferase as well as the stimulation of bile
acid excretion transporters Bsep, Mrp2, Mrp3, and Mrp4 (Fig. 1)
[6]. These orchestrated effects were anticipated to reduce hepato-
cyte oxidative stress by limiting bile acid toxicity and to facilitate
canalicular as well as adaptive basolateral efﬂux of accumulating
bile acids and bilirubin and therefore to ameliorate cholestatic
liver injury. Thus, there was a clear molecular rationale to test
oltipraz in a model of cholestatic liver disease.
For their experiments Weerachayphorn et al. chose a preven-
tive protocol and rather short duration of BDL. They treated mice
with oltipraz (150 mg/kg b.w.) 5 days prior to BDL and 3 days
thereafter. Contradictory to the authors’ expectations, oltipraz
treatment in BDL mice led to aggravation of liver injury with
extensive necroinﬂammation with signiﬁcantly increased extent
of bile infarcts affecting more than 20% of the liver parenchyma.
TUNEL-positive hepatocytes were not increased in oltipraz-
treated BDL mice, suggesting that necrosis rather than apoptosis
represented the main type of cell death. This is in line with pre-
vious observations in BDL mice and rats [7–9]. The authors were
not able to study later time points after BDL because the oltipraz-
treated mice died quickly following BDL. This is an interesting
parallel to the ﬁndings in UDCA-treated BDL mice [10]. Increased
bile ﬂow and biliary pressure, as induced by UDCA, was14 vol. 60 j 12–15
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Fig. 1. Potential targets for drug therapy in cholestatic liver diseases. Cyp 3a4/7a1/8b1, cytochrome p450 family member proteins; BSEP, bile salt export pump; CAR,
constitutive androgen receptor; ET-1, endothelin-1; FGF, ﬁbroblast growth factor; FXR, farnesoid X receptor; GSS, glutathione synthetase; ICAM-1, intercellular adhesion
molecule 1; LOXL-2, lysyloxidase homolog 2; M3R, muscarine-3 receptor; MDR3, multidrug-resistance related protein 3; MMPs, matrix metalloproteases; MPO,
myeloperoxidase; MRP3/4, multidrug-resistance protein 3/4; MUCs, mucin core proteins; OATPs, organic anion transporting polypeptide; OSTa/b, organic solute
transporter a/b; PDGF, platelet derived growth factor; PXR, pregnane X receptor; RXR, retinoid X receptor; SctR, secretin receptor; SULT2a1, sulfotransferase2a1; TFF, trefoil
factor family; TGFb, transforming growth factor b; TGR5, membrane bound G-protein coupled bile acid receptor; TIMPs, tissue inhibitor of metalloproteinases; UGT 2B2,
UDP-glucuronyltransferase 2B2; VDR, vitamin D receptor; VGEF, vascular endothelial growth factor; ZO-1-3, tight junction associated protein zonula occludens 1–3.
JOURNAL OF HEPATOLOGYpreviously shown to represent a pivotal trigger for the speciﬁc
type of liver injury including characteristic bile infarcts in BDL
mice [10–12]. The authors therefore determined bile ﬂow in
response to olpitraz and they indeed found a substantial increase
in bile acid-independent bile ﬂow primarily attributable to
increased biliary GSH secretion. Moreover, olpitraz enhanced
hepatic GSH content and stimulated Mrp4 expression as sug-
gested. In contrast, there were no differences in Mrp2, Bsep, and
Mrp3 expression compared to controls. Based on these ﬁndings
the authors conclude that olpitraz increased liver injury in BDL
mice primarily due to increased bile acid-independent GSH-med-
iated bile ﬂow leading to a critical biliary pressure, so supporting
the concept that increased ﬂow rates in an obstructed biliary tree
may be detrimental [10]. They conclude that olpitraz should beJournal of Hepatology 20avoided in patients whose cholestasis is due to or associated with
bile duct obstruction.
Does this mean the end for olpitraz as an anticholestatic
agent? Before drawing such a deﬁnite conclusion mouse models
of cholestatic liver diseases should be reviewed carefully [13].
First we should keep in mind that mice and humans differ sub-
stantially in major determinants of cholestatic liver injury such
as bile acid composition and the relative amount of bile acid-
dependent/independent bile ﬂow. In addition, the question must
be raised as to which speciﬁc aspects of the BDL mouse model are
relevant in relation to human cholestatic liver diseases other than
simple bile duct obstruction due to stone or tumor. Since its ﬁrst
comprehensive description in the early 20th century, BDL has sig-
niﬁcantly helped us to understand bile formation and secretion as14 vol. 60 j 12–15 13
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Fig. 2. Mechanisms and characteristics of liver injury in bile duct ligated mice.
Editorialwell as lipid metabolism and associated regulatory mechanisms.
With regard to the pathophysiology of cholestatic liver diseases,
BDL is particularly suitable to study the consequences of chole-
stasis due to total bile duct obstruction with a characteristic liver
phenotype comprising bile infarcts (reﬂecting foci of lytic necro-
sis of hepatocytes due to regurgitated bile with millimolar con-
centration of bile acids out of disrupted canals of Herring),
ductular reaction and biliary ﬁbrosis. Since the pathological
changes are deﬁnitive, the cholestatic phenotype in BDL mice is
hard to overcome pharmacologically, as outlined recently in more
detail elsewhere [13] (Fig. 2). Therefore, the BDL model is not
well suited for treatment studies, especially in the case of chole-
retic drugs, which will always carry the risk of worsening bile
infarcts due to high biliary pressure. It so would be premature
to dismiss oltipraz for the treatment of cholestasic liver disease
in general solely based on negative ﬁndings in BDL mice. One
should also test alternative models such as Abcb4/ mice or
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice mod-
eling sclerosing cholangitis with biliary ﬁbrosis, since these have
different pathogenesis and show a more diverse degree and
dynamic of cholestasis than do BDL mice [14]. Testing promising
drug candidates in different experimental models of cholestasis
could give important answers, e.g., as to whether oltipraz could
be beneﬁcial at different stages of cholestatic liver injury (i.e.,
early vs. late disease). In a broader context we should discuss
whether testing a potential novel drug for cholestasis and chole-
static liver disease should always be done in different models in14 Journal of Hepatology 20parallel as it has become standard for experimental liver ﬁbrosis
(e.g., combinations of CCl4-intoxicated, BDL, DDC-fed, porcine
serum-treated mice). Nevertheless, BDL mice still represent an
interesting model for several open questions in the pathophysiol-
ogy of cholestasis: (i) Why do BDL mice not develop bile plugs
whereas this is a characteristic ﬁnding in obstructive cholestasis
in humans? (ii) Do mice develop cholate stasis like humans and
what does this characteristic morphological sign mean? (iii)
How do regenerating hepatocytes ﬁnd their access to bile ducts?
(iv) Why do bile ducts proliferate from portal ﬁeld to portal ﬁeld?
Not to forget that BDL rodents, which have the highest degree of
cholestasis within models of cholestatic liver disease, may be par-
ticularly suited to study the pathobiology of important extrahe-
patic problems such as adrenal insufﬁciency and acute kidney
injury [15,16].
Weerachayaphorn et al. again teach us caution with choleretic
drugs in cholestatic liver diseases with an obstructive compo-
nent, as is the case in several cholangiopathies (e.g., PSC, SSC,
SSC-CIP). The current study also reminds us that the time point
for starting a drug always matters greatly in cholestatic liver dis-
eases. Probably there is a point of no return, especially in the case
of cholangiopathies, where drugs may potentially be harmful.
This may come into play especially for choleretic drugs when
one falls below a critical number of functional secretory units
of the liver (probably comparable to the nephron in kidney)
and there is no emergency exit for bile. The ‘‘ideal drug (cock-
tail?) for cholestasis’’ will in addition not only increase bile ﬂow14 vol. 60 j 12–15
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and restore excretory liver function or enhance alternative excre-
tory routes, but also in parallel resolve the underlying defect in
the liver. Since this has not yet been completely evaluated, the
case of oltipraz for cholestatic liver disease may still be open.Conﬂict of interest
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